This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welzel, T. M.
Right arrow Articles by Ortiz-Conde, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welzel, T. M.
Right arrow Articles by Ortiz-Conde, B. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2006, p. 3325-3333, Vol. 44, No. 9
0095-1137/06/$08.00+0     doi:10.1128/JCM.00024-06

Real-Time PCR Assay for Detection and Quantification of Hepatitis B Virus Genotypes A to G

Tania M. Welzel,1 Wendell J. Miley,2 Thomas L. Parks,2 James J. Goedert,1 Denise Whitby,2 and Betty A. Ortiz-Conde2*

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20892,1 Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, NCI-Frederick, P.O. Box B, Frederick, Maryland 217022

Received 5 January 2006/ Accepted 3 April 2006

The detection and quantification of hepatitis B virus (HBV) DNA play an important role in diagnosing and monitoring HBV infection as well as assessing therapeutic response. The great variability among HBV genotypes and the enormous range of clinical HBV DNA levels present challenges for PCR-based amplification techniques. In this study, we describe the development, evaluation, and validation of a novel real-time PCR assay designed to provide accurate quantification of DNA from all eight HBV genotypes in patient plasma specimens. A computer algorithm was used to design degenerate real-time PCR primers and probes based upon a large number (n = 340) of full-length genomic sequences including HBV genotypes A to H from Europe, Africa, Asia, and North and South America. Genotype performance was tested and confirmed using 59 genotype A to G specimens from two commercially available worldwide genotype panels. This assay has a dynamic range of at least 8 log10 without the need for specimen dilution, good clinical intra- and interassay precision, and excellent correlation with the Bayer Diagnostics VERSANT HBV DNA 3.0 (branched DNA) assay (r = 0.93). Probit analysis determined the 95% detection level was 56 IU/ml, corresponding to 11 copies per PCR well. The high sensitivity, wide linear range, good reproducibility, and genotype inclusivity, combined with a small sample volume requirement and low cost, make this novel quantitative HBV real-time PCR assay particularly well suited for application to large clinical and epidemiological studies.

* Corresponding author. Mailing address: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, NCI-Frederick, P.O. Box B, Frederick, MD 21702. Phone: (301) 846-7533. Fax: (301) 846-7119. E-mail: conde{at}ncifcrf.gov.

Journal of Clinical Microbiology, September 2006, p. 3325-3333, Vol. 44, No. 9
0095-1137/06/$08.00+0     doi:10.1128/JCM.00024-06






Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»